BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29343986)

  • 1. Radiotherapy for esophageal carcinoma: dose, response and survival.
    Luo Y; Mao Q; Wang X; Yu J; Li M
    Cancer Manag Res; 2018; 10():13-21. PubMed ID: 29343986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation field size and dose determine oncologic outcome in esophageal cancer.
    Gemici C; Yaprak G; Batirel HF; Ilhan M; Mayadagli A
    World J Surg Oncol; 2016 Oct; 14(1):263. PubMed ID: 27737673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas.
    Cheng N; Liu Y; Zhao G; Xu Y; Zhang T; Chen Y; Yan G; Hu Y; Yao S; Wang Z; Wang C; Chen Z; Hu Z; Liu D; Chen T
    Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):340-348. PubMed ID: 31655197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy.
    Sonnick MA; Oro F; Yan B; Desai A; Wu AJ; Shi W; Zhang Z; Gelblum DY; Paik PK; Yorke ED; Rosenzweig KE; Chaft JE; Rimner A
    Clin Lung Cancer; 2018 Jan; 19(1):e131-e140. PubMed ID: 28756051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Radiat Oncol; 2017 Aug; 12(1):131. PubMed ID: 28810885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of modern high-dose versus standard-dose radiation in definitive concurrent chemo-radiotherapy on outcome of esophageal squamous cell cancer: a meta-analysis.
    Luo HS; Huang HC; Lin LX
    Radiat Oncol; 2019 Oct; 14(1):178. PubMed ID: 31623639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma.
    Lertbutsayanukul C; Tharavej C; Klaikeaw N; Prayongrat A; Lowanitchai C; Sriuranpong V
    Thorac Cancer; 2017 May; 8(3):219-228. PubMed ID: 28322515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial.
    Welsh JW; Seyedin SN; Allen PK; Hofstetter WL; Ajani JA; Chang JY; Gomez DR; Amini A; Swisher SG; Blum MA; Younes AI; Nguyen QN; Minsky BD; Erasmus JJ; Lee JH; Bhutani M; Komaki RU
    J Thorac Oncol; 2017 Feb; 12(2):375-382. PubMed ID: 27794500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
    Reboul FL
    Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
    Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
    Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic analysis of definitive radiotherapy for early esophageal carcinoma(T1-2N0M0): a multi-center retrospective study of Jing-Jin-ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group].
    Lu N; Wang X; Li C; Wang L; Chen JQ; Zhang WC; Wang XM; Ge XL; Shen WB; Hu MM; Yuan QQ; Xu YG; Hao CL; Zhou ZG; Qie S; Xiao ZF; Zhu SC; Han C; Qiao XY; Pang QS; Wang P; Zhao YD; Sun XC; Zhang KX; Li L; Li GF; Liu ML; Wang YD
    Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):139-144. PubMed ID: 32135649
    [No Abstract]   [Full Text] [Related]  

  • 14. Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy.
    Kim HJ; Suh YG; Lee YC; Lee SK; Shin SK; Cho BC; Lee CG
    Cancer Res Treat; 2017 Jul; 49(3):669-677. PubMed ID: 27737537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy.
    Zhang Z; Liao Z; Jin J; Ajani J; Chang JY; Jeter M; Guerrero T; Stevens CW; Swisher S; Ho L; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):656-64. PubMed ID: 15708243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation Therapy for Locally Advanced Esophageal Cancer.
    Chun SG; Skinner HD; Minsky BD
    Surg Oncol Clin N Am; 2017 Apr; 26(2):257-276. PubMed ID: 28279468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.
    Murakami M; Kuroda Y; Okamoto Y; Kono K; Yoden E; Kusumi F; Hajiro K; Matsusue S; Takeda H
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1049-59. PubMed ID: 9539559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose definitive concomitant chemoradiotherapy in non-metastatic locally advanced esophageal cancer: toxicity and outcome.
    Hurmuzlu M; Monge OR; Smaaland R; Viste A
    Dis Esophagus; 2010 Apr; 23(3):244-52. PubMed ID: 19664075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do Higher Radiation Doses with Concurrent Chemotherapy in the Definitive Treatment of Esophageal Cancer Improve Outcomes? A Meta-Analysis and Systematic Review.
    Xiao L; Czito BG; Pang Q; Hui Z; Jing S; Shan B; Wang J
    J Cancer; 2020; 11(15):4605-4613. PubMed ID: 32489478
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone.
    Chen Y; Lu Y; Wang Y; Yang H; Xia Y; Chen M; Song H; Li T; Li D; Wang J; Li S; Wang J
    Dis Esophagus; 2014; 27(2):134-40. PubMed ID: 23088212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.